Rogier W Sanders

List of Publications by Year
in descending order

198 papers	21,483 citations	11651 70 h-index	11939 134 g-index
233 all docs	233 docs citations	233 times ranked	15464 citing authors

#	Article	IF	Citations
1	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science, 2020, 369, 643-650.	12.6	1,104
2	A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies. PLoS Pathogens, 2013, 9, e1003618.	4.7	835
3	Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer. Science, 2013, 342, 1477-1483.	12.6	793
4	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014, 509, 55-62.	27.8	681
5	Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer. Science, 2013, 342, 1484-1490.	12.6	662
6	A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield. Science, 2011, 334, 1097-1103.	12.6	644
7	The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120. Journal of Virology, 2002, 76, 7293-7305.	3.4	528
8	A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure. Journal of Virology, 2000, 74, 627-643.	3.4	503
9	HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 2015, 349, aac4223.	12.6	482
10	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Science Immunology, 2021, 6, .	11.9	455
11	Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1. Journal of Virology, 2002, 76, 8875-8889.	3.4	424
12	Broad and potent HIV-1 neutralization by a human antibody that binds the gp41â€“gp120 interface. Nature, 2014, 515, 138-142.	27.8	400
13	Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immunity, 2014, 40, 657-668.	14.3	342
14	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell, 2015, 163, 1702-1715.	28.9	341
15	Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17624-17629.	7.1	324
16	Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers. Immunity, 2014, 40, 669-680.	14.3	323
17	Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nature Structural and Molecular Biology, 2013, 20, 796-803.	8.2	314
18	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science, 2021, 373, 818-823.	12.6	309

#	Article	IF	Citations
19	Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6639-E6648.	7.1	286
20	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity, 2017, 46, 1073-1088.e6.	14.3	286
21	Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans. PLoS Pathogens, 2013, 9, e1003342.	4.7	267
22	Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell Reports, 2016, 14, 2695-2706.	6.4	250
23	A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene. Journal of Virology, 2015, 89, 3380-3395.	3.4	247
24	Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science, 2021, 371, .	12.6	244
25	Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell, 2015, 161, 1505-1515.	28.9	239
26	Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4351-4356.	7.1	236
27	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science, 2021, 374, 472-478.	12.6	228
28	Nativeâ€like Env trimers as a platform for <scp>HIV</scp>â€1 vaccine design. Immunological Reviews, 2017, 275, 161-182.	6.0	221
29	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. Cell Reports, 2016, 16, 2327-2338.	6.4	216
30	The microanatomic segregation of selection by apoptosis in the germinal center. Science, 2017, 358, .	12.6	204
31	Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. Immunity, 2015, 43, 1053-1063.	14.3	200
32	The effect of spike mutations on SARS-CoV-2 neutralization. Cell Reports, 2021, 34, 108890.	6.4	200
33	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity, 2020, 53, 1272-1280.e5.	14.3	185
34	Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. Cell Reports, 2017, 20, 1805-1817.	6.4	171
35	High titers and low fucosylation of early human antiâ€“SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Science Translational Medicine, 2021, 13, .	12.4	166
36	Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology, 2015, 12, 82.	2.0	156

#	Article	IF	Citations
37	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell, 2021, 184, 1188-1200.e19.	28.9	154
38	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. Immunity, 2019, 50, 241-252.e6.	14.3	153
39	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. Cell Reports, 2020, 33, 108274.	6.4	152
40	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. Journal of Experimental Medicine, 2017, 214, 2573-2590.	8.5	151
41	Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein. Journal of Virology, 2002, 76, 7760-7776.	3.4	150
42	Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. Cell Reports, 2016, 17, 2195-2209.	6.4	150
43	Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nature Communications, 2019, 10, 4272.	12.8	149
44	Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. Journal of Virology, 2015, 89, 10383-10398.	3.4	148
45	Differential Transmission of Human Immunodeficiency Virus Type 1 by Distinct Subsets of Effector Dendritic Cells. Journal of Virology, 2002, 76, 7812-7821.	3.4	144
46	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature Microbiology, 2017, 2, 16199.	13.3	144
47	Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology, 2014, 11, 41.	2.0	139
48	Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. PLoS Pathogens, 2016, 12, e1005864.	4.7	138
49	HIV-1 gp120 Mannoses Induce Immunosuppressive Responses from Dendritic Cells. PLoS Pathogens, 2007, 3, e169.	4.7	135
50	Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Cell Reports, 2015, 11, 1604-1613.	6.4	135
51	Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins. Journal of Virology, 2002, 76, 2606-2616.	3.4	133
52	Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nature Communications, 2015, 6, 6144.	12.8	130
53	Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. Journal of Immunology, 2016, 197, 994-1002.	0.8	130
54	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Science Translational Medicine, 2017, 9, .	12.4	128

#	Article	IF	Citations
55	Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11947-11952.	7.1	127
56	Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. ELife, 2020, 9, .	6.0	123
57	Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. Cell Reports, 2018, 24, 1958-1966.e5.	6.4	120
58	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature Communications, 2019, 10, 2355.	12.8	116
59	Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathogens and Immunity, 2021, 6, 116-134.	3.1	112
60	Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. PLoS Pathogens, 2018, 14, e1006913.	4.7	111
61	CD4-Induced Activation in a Soluble HIV-1 Env Trimer. Structure, 2014, 22, 974-984.	3.3	108
62	SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. Science Advances, 2021, 7, .	10.3	107
63	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell, 2020, 180, 471-489.e22.	28.9	106
64	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathogens, 2020, 16, e1008817.	4.7	105
65	Broadly neutralizing antibodies against HIV-1: Templates for a vaccine. Virology, 2013, 435, 46-56.	2.4	104
66	Comprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer. PLoS Pathogens, 2015, 11, e1004767.	4.7	100
67	HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. Trends in Immunology, 2016, 37, 221-232.	6.8	96
68	Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. Journal of Virology, 2015, 89, 12189-12210.	3.4	88
69	Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nature Communications, 2015, 6, 8167.	12.8	87
70	Three mutations switch H7N9 influenza to human-type receptor specificity. PLoS Pathogens, 2017, 13, e1006390.	4.7	83
71	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. Science Advances, 2021, 7, eabj5365.	10.3	83
72	Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS Pathogens, 2015, 11, e1005110.	4.7	78

#	Article	IF	Citations
73	cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIVâ€1 envelope glycoprotein vaccine candidate. Biotechnology and Bioengineering, 2018, 115, 885-899.	3.3	75
74	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS Medicine, 2022, 19, e1003991.	8.4	75
75	Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology, 2010, 401, 236-247.	2.4	72
76	Detailed Mechanistic Insights into HIV-1 Sensitivity to Three Generations of Fusion Inhibitors. Journal of Biological Chemistry, 2009, 284, 26941-26950.	3.4	71
77	Virus vaccines: proteins prefer prolines. Cell Host and Microbe, 2021, 29, 327-333.	11.0	70
78	How Can HIV-Type-1-Env Immunogenicity Be Improved to Facilitate Antibody-Based Vaccine Development?. AIDS Research and Human Retroviruses, 2012, 28, 1-15.	1.1	69
79	Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. Acta Crystallographica Section D: Biological Crystallography, 2015, 71, 2099-2108.	2.5	69
80	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Reports, 2017, 18, 2175-2188.	6.4	69
81	Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. Journal of Virology, 2018, 92, .	3.4	66
82	Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. Journal of Virology, 2019, 93, .	3.4	66
83	Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. ELife, 2021, 10, .	6.0	63
84	Immunosilencing a Highly Immunogenic Protein Trimerization Domain. Journal of Biological Chemistry, 2015, 290, 7436-7442.	3.4	62
85	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity, 2018, 49, 1162-1174.e8.	14.3	61
86	Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics. PLoS Pathogens, 2019, 15, e1007920.	4.7	61
87	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. PLoS Pathogens, 2020, 16, e1008753.	4.7	61
88	Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. Journal of Virology, 2017, 91, .	3.4	57
89	Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits. Journal of Virology, 2020, 94, .	3.4	57
90	Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity. Nutrients, 2021, 13, 1645.	4.1	54

#	Article	IF	Citations
91	Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. Biochemistry, 2021, 60, 2153-2169.	2.5	54
92	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. PLoS Pathogens, 2020, 16, e1008665.	4.7	52
93	Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology, 2009, 389, 108-121.	2.4	50
94	Infection and transmission of SARSâ€CoVâ€2 depend on heparan sulfate proteoglycans. EMBO Journal, 2021, 40, e106765.	7.8	50
95	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host and Microbe, 2021, 29, 806-818.e6.	11.0	49
96	Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions. Structure, 2020, 28, 897-909.e6.	3.3	46
97	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Advances, 2022, 6, 1537-1546.	5.2	45
98	Only Five of 10 Strictly Conserved Disulfide Bonds Are Essential for Folding and Eight for Function of the HIV-1 Envelope Glycoprotein. Molecular Biology of the Cell, 2008, 19, 4298-4309.	2.1	44
99	HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. Expert Review of Vaccines, 2016, 15, 349-365.	4.4	44
100	A single mutation in Taiwanese H6N1 influenza hemagglutinin switches binding to humanâ€type receptors. EMBO Molecular Medicine, 2017, 9, 1314-1325.	6.9	44
101	Optimization of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins with V1/V2 Deleted, Using Virus Evolution. Journal of Virology, 2009, 83, 368-383.	3.4	43
102	In vivo protection by broadly neutralizing HIV antibodies. Trends in Microbiology, 2014, 22, 550-551.	7.7	43
103	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS Pathogens, 2015, 11, e1005238.	4.7	43
104	The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology, 2008, 5, 10.	2.0	42
105	Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. Virology, 2015, 486, 116-120.	2.4	42
106	Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. Cell Host and Microbe, 2019, 25, 873-883.e5.	11.0	42
107	Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?. Cell Host and Microbe, 2020, 27, 507-518.	11.0	42
108	Structure and topology around the cleavage site regulate post-translational cleavage of the HIV-1 gp160 signal peptide. ELife, 2017, 6, .	6.0	41

#	Article	IF	Citations
109	Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. Journal of Biological Chemistry, 2018, 293, 1688-1701.	3.4	40
110	HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. Retrovirology, 2013, 10, 102.	2.0	39
111	Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. Journal of Allergy and Clinical Immunology, 2022, 149, 1949-1957.	2.9	39
112	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nature Communications, 2021, 12, 6097.	12.8	38
113	Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. Cell Reports, 2021, 35, 108933.	6.4	37
114	Variable Domain N-Linked Glycans Acquired During Antigen-Specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability. Frontiers in Immunology, 2018, 9, 740.	4.8	35
115	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nature Communications, 2021, 12, 4817.	12.8	35
116	Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. Journal of Virology, 2016, 90, 813-828.	3.4	34
117	Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. Retrovirology, 2018, 15, 63.	2.0	34
118	Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41. Retrovirology, 2004, 1, 3.	2.0	33
119	Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. Npj Vaccines, 2021, 6, 24.	6.0	33
120	Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide. Nature Communications, 2019, 10, 763.	12.8	30
121	A stamp on the envelope. Nature, 2014, 514, 437-438.	27.8	29
122	Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. Journal of Virology, 2020, 94, .	3.4	29
123	Pandemic moves and countermoves: vaccines and viral variants. Lancet, The, 2021, 397, 1326-1327.	13.7	29
124	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. PLoS Pathogens, 2018, 14, e1006986.	4.7	28
125	ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1296-1305.	2.6	27
126	Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. Journal of Virology, 2017, 91, .	3.4	27

#	Article	IF	Citations
127	Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms. Current Opinion in HIV and AIDS, 2019, 14, 302-308.	3.8	27
128	What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?. Journal of Virology, 2015, 89, 5981-5995.	3.4	25
129	HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry. Journal of Biological Chemistry, 2019, 294, 5736-5746.	3.4	24
130	Structureâ€guided envelope trimer design in HIVâ€1 vaccine development: a narrative review. Journal of the International AIDS Society, 2021, 24, e25797.	3.0	24
131	Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. Journal of Proteome Research, 2018, 17, 987-999.	3.7	23
132	Protein Promiscuity: Drug Resistance and Native Functionsâ€"HIV-1 Case. Journal of Biomolecular Structure and Dynamics, 2005, 22, 615-624.	3.5	22
133	High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. Journal of Virology, 2017, 91, .	3.4	22
134	Evolutionary Repair of HIV Type 1 gp41 with a Kink in the N-Terminal Helix Leads to Restoration of the Six-Helix Bundle Structure. AIDS Research and Human Retroviruses, 2004, 20, 742-749.	1.1	21
135	HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. Retrovirology, 2016, 13, 48.	2.0	20
136	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. ACS Central Science, 2021, 7, 1863-1873.	11.3	20
137	Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers. Aids, 2014, 28, 1237-1240.	2.2	19
138	HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite. Science Advances, 2020, 6, eaba0512.	10.3	18
139	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. PLoS Pathogens, 2021, 17, e1009736.	4.7	18
140	Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens. Journal of Pharmaceutical Sciences, 2019, 108, 2264-2277.	3.3	16
141	Stabilization of the V2 loop improves the presentation of V2 loopâ€"associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. Journal of Biological Chemistry, 2019, 294, 5616-5631.	3.4	16
142	Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination. EBioMedicine, 2021, 72, 103589.	6.1	16
143	HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PLoS ONE, 2017, 12, e0181886.	2.5	16
144	A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. Cell Reports Medicine, 2022, 3, 100486.	6.5	16

#	Article	IF	Citations
145	Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein. AIDS Research and Human Retroviruses, 2015, 31, 1160-1165.	1.1	14
146	A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. Npj Vaccines, 2021, 6, 146.	6.0	14
147	Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. Journal of Experimental Medicine, 2022, 219, .	8.5	14
148	Influenza A Virus Hemagglutinin Trimer, Head and Stem Proteins Identify and Quantify Different Hemagglutinin-Specific B Cell Subsets in Humans. Vaccines, 2021, 9, 717.	4.4	13
149	The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. Journal of Virology, 2022, 96, JVI0155221.	3.4	13
150	High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers. Npj Vaccines, 2022, 7, 27.	6.0	13
151	Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns. PLoS Pathogens, 2022, 18, e1010340.	4.7	13
152	Evolution Rescues Folding of Human Immunodeficiency Virus-1 Envelope Glycoprotein GP120 Lacking a Conserved Disulfide Bond. Molecular Biology of the Cell, 2008, 19, 4707-4716.	2.1	12
153	Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer. Biomolecules, 2015, 5, 2919-2934.	4.0	12
154	Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. Journal of Virology, 2019, 93, .	3.4	12
155	Colorectal Mucus Binds DC-SIGN and Inhibits HIV-1 Trans-Infection of CD4+ T-Lymphocytes. PLoS ONE, 2015, 10, e0122020.	2.5	11
156	The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype. AIDS Research and Human Retroviruses, 2016, 32, 1135-1142.	1.1	11
157	Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. Journal of Virology, 2020, 94, .	3.4	11
158	Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses. Vaccines, 2021, 9, 750.	4.4	11
159	A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. Scientific Reports, 2022, 12, 3884.	3.3	11
160	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. Journal of Virology, 2022, 96, JVI0134321.	3.4	10
161	Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits. Journal of Virology, 2000, 74, 5091-5100.	3.4	9
162	SARSâ€CoVâ€2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs. European Journal of Immunology, 2022, 52, 646-655.	2.9	9

#	Article	IF	Citations
163	Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. Vaccines, 2020, 8, 440.	4.4	8
164	Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. Npj Vaccines, 2021, 6, 103.	6.0	8
165	D-101â€ƒHIV-1 neutralizing antibodies induced by native-like envelope trimers. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 52.	2.1	7
166	Short Communication: Protective Efficacy of Broadly Neutralizing Antibody PGDM1400 Against HIV-1 Challenge in Humanized Mice. AIDS Research and Human Retroviruses, 2018, 34, 790-793.	1.1	7
167	Intramolecular quality control: HIV-1 envelope gp160 signal-peptide cleavage as a functional folding checkpoint. Cell Reports, 2021, 36, 109646.	6.4	7
168	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. ELife, 0, 11, .	6.0	7
169	Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. Viruses, 2019, 11, 384.	3.3	6
170	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. Cell Reports Medicine, 2022, 3, 100528.	6.5	6
171	Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions. Frontiers in Immunology, 2022, 13, .	4.8	6
172	B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates. Cell Reports, 2022, 39, 111021.	6.4	6
173	Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-NaÃ¯ve Chronically HIV-1 Infected Individuals. PLoS ONE, 2015, 10, e0120648.	2.5	5
174	Harnessing post-translational modifications for next-generation HIV immunogens. Biochemical Society Transactions, 2018, 46, 691-698.	3.4	5
175	Reactivation of Neutralized HIV-1 by Dendritic Cells Is Dependent on the Epitope Bound by the Antibody. Journal of Immunology, 2015, 195, 3759-3768.	0.8	4
176	Hitting HIVâ€™s Harpoon. Immunity, 2018, 49, 14-15.	14.3	4
177	Production of HIV-1 Env-Specific Antibodies Mediating Innate Immune Functions Depends on Cognate Interleukin-21- Secreting CD4 ⁺ T Cells. Journal of Virology, 2021, 95, .	3.4	4
178	Computed tomography and [18F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates. IScience, 2022, 25, 104101.	4.1	4
179	HIV takes double hit before entry. BMC Biology, 2012, 10, 99.	3.8	3
180	A Recombinant HIV Envelope Trimer Selects for Quaternary Dependent Antibodies Targeting the Trimer Apex. AIDS Research and Human Retroviruses, 2014, 30, A7-A8.	1.1	3

#	Article	IF	Citations
181	Broadly neutralising antibodies in post-treatment control. Lancet HIV,the, 2019, 6, e271-e272.	4.7	3
182	Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL. PLoS ONE, 2014, 9, e107683.	2.5	3
183	Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination. Diagnostic Microbiology and Infectious Disease, 2022, 102, 115650.	1.8	3
184	Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Cell Reports Medicine, 2022, 3, 100635.	6.5	3
185	Opposites attract in bispecific antibody engineering. Journal of Biological Chemistry, 2017, 292, 14718-14719.	3.4	2
186	The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1. Frontiers in Immunology, 2019, 10, 2793.	4.8	2
187	Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice. MAbs, 2020, 12, 1845908.	5.2	2
188	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. Npj Vaccines, 2022, 7, 44.	6.0	2
189	Bypass of Quality Control in Protein Folding Pathways Induces Specific Misfolding of HIV Envelope V2 Loop: Implications for Iminosugars as Antivirals. AIDS Research and Human Retroviruses, 2014, 30, A49-A49.	1.1	0
190	Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface. Journal of Virology, 2021, 95, e0053221.	3.4	0
191	Title is missing!. , 2020, 16, e1008665.		0
192	Title is missing!. , 2020, 16, e1008665.		0
193	Title is missing!. , 2020, 16, e1008665.		0
194	Title is missing!. , 2020, 16, e1008665.		0
195	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
196	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
197	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
198	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0